TISSIUM is a privately-owned medtech company based in Paris, France and Boston, USA that is dedicated to the development and commercialization of a unique biopolymer platform to address multiple unmet clinical needs, including atraumatic tissue repair and reconstruction.
Affiliated to global investment firm Cathay Capital, Cathay Health is a global cross-border platform investing at the convergence of healthcare, life sciences and technology.
Cathay Health led new investors and joined other institutional and individual backers while existing shareholders were led by Sofinnova Partners, a historical cornerstone investor of Tissium.
This latest funding round coincides with a period of rapid growth at TISSIUM that is expected to continue as it scales its operations and adds to its executive team. The financing will allow TISSIUM to continue to execute on its development plan, funding the company up to the commercialization of its leading nerve repair, hernia repair and cardiovascular sealant products.
The Goodwin team was led by Anne-Charlotte Rivière on corporate aspects.
For more information, please read the press release.